Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Receivables: 2010-2024

Historic Change in Receivables for Catalyst Pharmaceuticals (CPRX) over the last 8 years, with Dec 2024 value amounting to $12.0 million.

  • Catalyst Pharmaceuticals' Change in Receivables rose 3606.22% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year increase of 371.20%. This contributed to the annual value of $12.0 million for FY2024, which is 72.23% down from last year.
  • Catalyst Pharmaceuticals' Change in Receivables amounted to $12.0 million in FY2024, which was down 72.23% from $43.1 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Change in Receivables ranged from a high of $43.1 million in FY2023 and a low of -$4.5 million during FY2020.
  • Its 3-year average for Change in Receivables is $19.6 million, with a median of $12.0 million in 2024.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Change in Receivables crashed by 143.17% in 2020, and later spiked by 1,027.62% in 2023.
  • Catalyst Pharmaceuticals' Change in Receivables (Yearly) stood at -$4.5 million in 2020, then skyrocketed by 113.89% to $632,000 in 2021, then soared by 504.43% to $3.8 million in 2022, then spiked by 1,027.62% to $43.1 million in 2023, then slumped by 72.23% to $12.0 million in 2024.